Pharming Group N.V. (PHAR), a global biopharmaceutical company developing and commercializing innovative protein replacement therapies and precision medicines for rare diseases, which showcased strong financial performance in the first quarter, is gearing up for a year of remarkable growth.
The company has two commercialized assets - Ruconest and Joenja. Ruconest, approved for the treatment of acute hereditary angioedema (HAE attacks, is marketed in the U.S., Europe and other countries. Joenja, the first and only approved disease modifying treatment for activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), is marketed in the U.S.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.